OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 32,329 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 22.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 179,266 shares of the company’s stock after acquiring an additional 32,329 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Roivant Sciences were worth $2,121,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its position in shares of Roivant Sciences by 478.6% in the 4th quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock worth $28,000 after acquiring an additional 1,948 shares during the period. Aster Capital Management DIFC Ltd acquired a new position in Roivant Sciences in the fourth quarter worth $39,000. GAMMA Investing LLC lifted its stake in shares of Roivant Sciences by 57.0% during the fourth quarter. GAMMA Investing LLC now owns 3,548 shares of the company’s stock valued at $42,000 after acquiring an additional 1,288 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Roivant Sciences by 27.0% during the fourth quarter. PNC Financial Services Group Inc. now owns 7,079 shares of the company’s stock valued at $84,000 after acquiring an additional 1,507 shares during the period. Finally, Wells Fargo & Company MN lifted its stake in shares of Roivant Sciences by 84.1% during the fourth quarter. Wells Fargo & Company MN now owns 7,501 shares of the company’s stock valued at $89,000 after acquiring an additional 3,426 shares during the period. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Trading Up 3.3%

Shares of NASDAQ ROIV opened at $10.99 on Tuesday. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06. The stock has a 50 day moving average of $10.49 and a 200-day moving average of $11.10. The company has a market capitalization of $7.84 billion, a P/E ratio of -73.26 and a beta of 1.23.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. Analysts predict that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ROIV. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Monday, April 21st. Cantor Fitzgerald raised Roivant Sciences to a “strong-buy” rating in a research report on Tuesday, March 4th.

Insider Transactions at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $10.22, for a total value of $1,022,000.00. Following the transaction, the chief operating officer now owns 1,116,345 shares in the company, valued at approximately $11,409,045.90. This represents a 8.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Vivek Ramaswamy sold 273,959 shares of the stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $11.47, for a total value of $3,142,309.73. Following the completion of the sale, the insider now directly owns 39,799,611 shares of the company’s stock, valued at approximately $456,501,538.17. This trade represents a 0.68% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,669,500 shares of company stock valued at $18,064,847. Corporate insiders own 7.90% of the company’s stock.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.